top of page
The Professional Network for Healthcare Experts
Sobi licenses lacutamab from Innate Pharma in T-cell lymphoma deal worth up to $580 million
The partnership gives Sobi potential global commercial and development rights to the first-in-class anti-KIR3DL2 antibody while funding Innate’s Phase III programme in cutaneous T-cell lymphoma.
nuaxia
5 days ago3 min read
Sobi moves to acquire full control of Pint Pharma to expand Latin American rare disease platform
The transaction would give Sobi full ownership of a specialist commercialisation platform spanning seven Latin American markets, building on its $105 million investment in Pint Pharma in 2025.
nuaxia
5 days ago3 min read
bottom of page